Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Current Assets (2016 - 2025)

Amicus Therapeutics (FOLD) has disclosed Current Assets for 16 consecutive years, with $676.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Assets rose 33.97% year-over-year to $676.2 million, compared with a TTM value of $676.2 million through Dec 2025, up 33.97%, and an annual FY2025 reading of $676.2 million, up 33.97% over the prior year.
  • Current Assets was $676.2 million for Q4 2025 at Amicus Therapeutics, up from $594.1 million in the prior quarter.
  • Across five years, Current Assets topped out at $676.2 million in Q4 2025 and bottomed at $399.7 million in Q1 2023.
  • Average Current Assets over 5 years is $506.2 million, with a median of $498.1 million recorded in 2022.
  • The sharpest move saw Current Assets dropped 29.51% in 2022, then soared 33.97% in 2025.
  • Year by year, Current Assets stood at $596.8 million in 2021, then decreased by 28.99% to $423.8 million in 2022, then rose by 13.98% to $483.1 million in 2023, then increased by 4.49% to $504.7 million in 2024, then soared by 33.97% to $676.2 million in 2025.
  • Business Quant data shows Current Assets for FOLD at $676.2 million in Q4 2025, $594.1 million in Q3 2025, and $538.0 million in Q2 2025.